Woman in Society

The first Inhibitor of world Integrasa for VIH/SIDA, ISENTRESS ® † (raltegravir)

Written for admin

Approved by the Department of Health in Panama the First Therapy in a New Class Directed to the Medical Need for the New Options of Treatment in Patients in Treatment Experienced. Panama, on July 17, 2009. – Merck Sharp and Dohme (MSD) announced today that the approval of raltegravir was granted by the Department of Health of Panama for his use in combination with other agents antirretrovirales for the treatment of the infection for VIH in patients with treatment experienced with replicación viral current in spite of therapy antirretroviral (TAR).1 1 Raltegravir is the first inhibitor of integrasa pass, a new class of TAR that works taking like the enzyme as white integrasa, that is essential for the replicación of the VIH.1,2 Like part of the available information, there are two separated clinical essays in which the raltegravir, in combination with other agents antirretrovirales, demonstrated to be effective in reducing the viral load and in increasing the count of cells CD4,3,4 the most recognized ways of measuring the efficacy against the infection of the VIH/SIDA.5 additional Investigations they demonstrated that raltegravir has been generally well be tolerated by it, with a profile of side effects comparable with those of placebo 3,4,6 “Raltegravir is a new important advance in the treatment of the VIH/SIDA, because it is the first therapy in a new class of medicines that attacks the virus of a completely different way,” there said Kenneth Frazier, president of Global Human Health, Merck and Co., Inc.“ The importance of this advance for the patients who cannot already be treated appropriately with traditional therapies must not be on emphasized, and MSD is compromised in doing that raltegravir and other options of new treatments and vaccines are accessible to the global VIH/SIDA community.” In spite of the medicines availability to treat the VIH/SIDA, the global epidemic continua.7 The resistance to the current therapies against VIH in patients in treatment experienced has been observed in numerous international studies, suggesting that the resistance to at least a class of agent antirretroviral can be so high as 76 per cent.

Cathar Ton Enel Fortuna/Kiwanis.

Written for admin

Finally the technology today can be a miracle for many persons who before so many advances did not have a lot of hopes to solve or to conquer diverse adversities that often we face in the life, this is the example of the patients selected by Cathar Ton that it celebrates in Panama annually, the same that it returns the sight to so many biggest adults who stopped doing so many things because they did not see due to the cataracts.

This July 10 and 11 it is celebrated in Panama the fourth It was looking ton at ENEL FORTUNA/KIWANIS favoring approximately 100 Panamanian ones of scarce resources of different places of our country and without right to social insurance, they will benefit in the center of ocular surgery.

These operations are a report of an agreement of social cooperation signed between the company E NEL FORTUNE AND THE CLUB KIWANIS OF PANAMA, that this year has taken special attention in the population chiricana, of the district of Gualaca, place where the central Hydroelectrics Enel Fortuna is and where after a detailed analysis realized by the health center of the area, 25 persons, of the whole that will be attended, will travel for interventions in the cardinal city with his accompanists.

Thanks to the patronage of the company Enel fortune, to the center of Ocular Surgery and his 18 associates surgeons ophthalmologists and to the foundation Provision 20-30, who will donate his time and knowledge to realize these 100 operations in two days, one can carry out this interesting initiative which entire cost climbs to B/250,000.00 balboas.

GARDASIL ® is the First Vaccine for Cancer Cervicouterino in being Precalificada for the WHO

Written for admin

Press bulletin

The Prequalification of the WHO will Facilitate the Extensive Access to World Level and the Execution of Programs of Vaccination Against the VPH. GARDASIL ® [it vaccinates recombinante tetravalente (types 6, 11, 16 and 18) for the human virus of the papilloma], the vaccine for cancer cervicouterino of Merck Sharp and Bulletin of press.

Dohme, has received the prequalification of the World Organization of the Health. This is the first vaccine for cancer cervicouterino in being prequalified by the WHO.

With the prequalification of the WHO, now the vaccine recombinante tetravalente (types 6, 11, 16 and 18) for the human virus of the papilloma, can be acquired by the Fund of the United Nations for the Infancy (UNICEF, United Nations Children's Fund) and other entities of the United Nations Organization (UNO), as well as of the Pan-American Organization of the Health (OPS) to use it in national vaccination programs.
“The commitment of Merck Sharp and Dohme is to guarantee the access to our vaccine. The prequalification of the WHO is an important measurement that allows to many women in the world to obtain the benefits of this significant advance in the women's health”, said Margaret G. McGlynn, the president of Vaccines and Infectious Illnesses of Merck Sharp and Dohme.
The prequalification of the WHO has the target to make sure that the vaccines expire with the criteria of the quality WHO, safety and efficacy, which, together with other criteria, serve to the UNO and other dependencies to decide his buys.
“The cancer cervicouterino is an important problem in the developing countries. The prequalification of the WHO of a vaccine against VPH means an advance to protect the young women and to have major access to a better medical attention, especially in the poorest countries”, mentioned Graça Machel, founder and the president of the Foundation for the Community development (FDC, Foundation for Community Development) on Mozambique and passionate advocate of the women's health.

To read more

|